Send Inquiry

Request To Call Back

250mg Gefitinib Tablet IP

Get a Price/Quote

MOQ : 10 Boxes

250mg Gefitinib Tablet IP Specification

Dosage Form
Tablet

Salt Composition
Gefitinib 250mg

Indication
Non-Small Cell Lung Cancer (NSCLC)

Enzyme Types
Tyrosine Kinase Inhibitor, Not applicable (Tyrosine kinase inhibitor)

Feature
Film-coated, precise dosage, easy-to-swallow, Oral, easy administration, film-coated for ease of swallowing

Ingredients
Gefitinib with inactive excipients, Gefitinib and excipients

Application
Oral administration for cancer therapy, Targeted therapy for cancer

Physical Color/Texture
White to off-white, round biconvex tablet, White to off-white, round film-coated tablet

Fermentation Smell
Odorless, Odorless

Enzymatic Activity
Inhibits EGFR tyrosine kinase activity

Storage Instructions
Store below 30C, protect from light and moisture

Shelf Life
24 months

Patient Advice
Take as directed by physician; not for use in children.

Packing Type
Box of 10*10 tablets / blister pack

Manufacturing Date
See box/blister

Molecular Formula
C22H24ClFN4O3

Expiry Date
See box/blister

Batch Number
Available on packaging

Contraindications
Known hypersensitivity to Gefitinib or its components

Prescription/Non-prescription
Prescription only

Regulatory Status
Approved in India under IP standards

Brand Name
Gefitinib Tablet IP 250mg

Tablet Markings
Tablet may contain identification markings/logos as per manufacturer.

Packaging Material
Aluminum-PVC blister strips

Administration Route
Oral

ATC Code
L01XE02

Manufacturer Details
As per packaging (see label)

Molecular Weight
446.9 g/mol

250mg Gefitinib Tablet IP Trade Information

Minimum Order Quantity
10 Boxes

Payment Terms
Cash Against Delivery (CAD), Cash on Delivery (COD), Cash in Advance (CID)

Supply Ability
100 Boxes Per Month

Delivery Time
5-7 Days

Main Domestic Market
All India

About 250mg Gefitinib Tablet IP

Highlighted as a new release, Gefitinib Tablet IP 250mg stands out with outstanding Favorable Reviews from healthcare professionals. Designed for the formidable challenge of treating Non-Small Cell Lung Cancer (NSCLC), these stellar film-coated tablets offer precise dosing and are easy to swallow, emphasizing patient convenience. Administered orally, each box contains 100 tablets (10x10 blister packs) of Gefitinib, a recognized tyrosine kinase inhibitor with a molecular formula of C22H24ClFN4O3. This product, odorless and round biconvex in shape, is approved in India under IP standards and demands prescription-only access.

Key Application and Benefits of Gefitinib Tablet IP 250mg

The primary site of application for Gefitinib Tablet IP 250mg is in targeted cancer therapy, specifically for patients with Non-Small Cell Lung Cancer (NSCLC). Its usage type is strictly oral and prescription-based, ensuring accurate patient management. Competitive advantages include film-coating for ease of swallowing, formidable efficacy due to precise dosage, and favorable patient compliance. The stellar therapeutic performance is enhanced by its inhibition of EGFR tyrosine kinase activity, offering a strategic edge in cancer treatment protocols.

Packing, Shipping, and Domestic Market Presence

Packing & Dispatch are managed with secure shipping protocols, ensuring the integrity of each box of 10x10 aluminum-PVC blister-packed tablets. Express Shipping is available for prompt delivery. FOB Port services are streamlined from leading hubs in India, with the Main Domestic Market encompassing major regions nationwide. Packaging details highlight robust, export-quality standards for trader, exporter, and supplier needs, providing assurance in both national and international consignments.

FAQ's of 250mg Gefitinib Tablet IP:

Q: How should Gefitinib Tablet IP 250mg be administered for optimal results?

A: Gefitinib Tablet IP 250mg should be taken orally as directed by your physician. Swallow the film-coated tablet whole with water, preferably at the same time each day, without breaking or crushing it.

Q: What is the primary benefit of using Gefitinib Tablet IP 250mg in NSCLC treatment?

A: Gefitinib 250mg offers targeted inhibition of EGFR tyrosine kinase, which helps slow the growth of cancer cells in patients with Non-Small Cell Lung Cancer (NSCLC), thus providing a formidable therapeutic advantage.

Q: When should I avoid taking Gefitinib Tablet IP 250mg?

A: Avoid Gefitinib Tablet IP 250mg if you have a known hypersensitivity to Gefitinib or any of its components. Always consult your physician regarding contraindications before starting therapy.

Q: Where can I check important batch and expiry details for Gefitinib Tablet IP 250mg?

A: Batch number, manufacturing date, and expiry date are available on the product's packaging, including the box or blister pack. Always verify these details before use.

Q: What packaging materials are used to ensure the safety and quality of Gefitinib Tablet IP 250mg?

A: Gefitinib Tablet IP 250mg is securely packed in aluminum-PVC blister strips placed inside robust carton boxes, providing optimal protection from light and moisture during storage and shipping.

Q: How should this medication be stored for maximum shelf life?

A: Store Gefitinib Tablet IP 250mg below 30C, in a dry place, and protect it from light and moisture to maintain its efficacy throughout the 24-month shelf life.

Tell us about your requirement